Browse News
Filter News
Found 4,976 articles
-
Oncopeptides AB: Year-end Report 2018
2/22/2019
At the company's Capital Markets Day in December, an updated strategy for Oncopeptides' business was presented
-
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
-
Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy
2/21/2019
In vivo studies demonstrate CD45 targeting ARC effectively lymphodepletes, allowing cells to expand while sparing bone marrow stem cells, red blood cells and platelets
-
Kesem Announces New CEO
2/21/2019
Kesem, a nationwide community that supports children through and beyond their parent's cancer, names Kim McCall Chief Executive Officer
-
bluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress
2/21/2019
bluebird bio, Inc. reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.
-
Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
2/21/2019
Data in severe aplastic anemia support potential of NiCord to treat non-malignant bone marrow failure disorders
-
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Monotherapy for Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer (SCLC)
2/20/2019
Merck announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA
-
eRace Cancer Says 78-Year-Old Don Wright—a 16-Year Cancer Survivor—to Run in Iowa Senior Games on February 23rd as He Gears up for the National Senior Games in June
2/20/2019
Don aims to improve his times in four events, while able to do so because of new medications that keep his cancer in check
-
WUGEN Presents New Data for Key CAR-T Platform at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR
2/20/2019
Presentations feature new preclinical data on WUGEN's core fratricide-resistant CAR-T therapy platform targeting T-cell malignancies
-
Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma
2/19/2019
Merck announced that the pivotal Phase 3 KEYNOTE-240 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy, did not meet its co-primary endpoints of overall survival and progression-free survival compared with placebo plus best supportive care.
-
Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
2/19/2019
Through this agreement, the companies aim to discover optimized NAM-NK cells that could be used to improve the treatment of hematologic malignancies and solid tumors.
-
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
2/19/2019
U.S. Approval Based on Significant Recurrence-Free Survival (RFS) Benefit Demonstrated with KEYTRUDA in Phase 3 EORTC1325/KEYNOTE-054 Trial
-
Mumbai-based Glenmark Pharmaceuticals is spinning off its innovation business into a standalone company based in the United States. The new business will have its own chief executive officer and board of directors.
-
Oncopeptides Will Host a Webcast in Conjunction With its Year-end Report 2018 on 22 February at 14.00 (CET)
2/18/2019
Oncopeptides AB announces that the Company will release its Year-end Report on 22 February at 8:00 am CET.
-
KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)
2/16/2019
Results from Phase 3 KEYNOTE-426 Study Presented Today at the 2019 Genitourinary Cancers Symposium (ASCO GU) and Published in the New England Journal of Medicine Also Showed Risk of Progression or Death Reduced by 31 Percent
-
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
2/15/2019
Application Based on Overall Survival and Progression-Free Survival Data from Phase 3 KEYNOTE-426 Trial
-
Self Care Catalysts and OncologyInformationService Announce Partnership to Generate Patient-centered Insights into Cancer Treatments in Europe
2/14/2019
Self Care Catalysts and the OncologyInformationService) are announcing a partnership to develop a patient-centered, real world dataset to drive advancements in cancer research.
-
Physicians’ Education Resource® Announces Dr. Tait Shanafelt as Keynote Speaker for the 23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
2/14/2019
Physicians’ Education Resource® (PER®), a leading resource for continuing medical education (CME), announced that Tait Shanafelt, M.D., will be the keynote speaker for the 23rd annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma.
-
Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting
2/14/2019
Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that it will host a conference call and webcast on Thursday, February 21, 2019, at 8:00 a.m. ET to review the data from its NAM-NK and NiCord® programs being presented at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood and Marrow Transplant Research
-
International Myeloma Foundation (IMF) Launches Myeloma Action Month March 1
2/14/2019
The International Myeloma Foundation (IMF) is harnessing the power of myeloma patients, their families, and the myeloma community at large to raise awareness of the disease during Myeloma Action Month (MAM), starting March 1, 2019